A modular system for the production of transcriptional activators
Human gene therapy entails the administration of genetic material to alter the expression of or modify endogenous genes. In cases where activation of gene expression is required, researchers transfer transcription factors – proteins necessary for gene transcription – to the target cells. The EU-funded Diverge project has developed a modular system that combines site-specific recombinase and molecular splicing to generate billions of transcription factor variants in vivo from a single construct. Researchers are exploring the potential to commercialise this system and expand the applicability of the technology in therapy and biotechnology.
Fields of science
Funding SchemeERC-POC - Proof of Concept Grant
SW7 2AZ London
See on map